Home›News›Clinical Trials›Cannabis Science Updates Cancer Patient Progress As It Receives Verbal Confirmation By A Physician That Both Sites Of The Former Lesions Are Free Of Cancer Cells; Official Physician Documentation To Follow

Cannabis Science Updates Cancer Patient Progress As It Receives Verbal Confirmation By A Physician That Both Sites Of The Former Lesions Are Free Of Cancer Cells; Official Physician Documentation To Follow

DENVER--(BUSINESS WIRE)--Mar 9, 2011 - Cannabis Science, Inc.
(OTCBB: CBIS) a pioneering U.S. biotech company developing
pharmaceutical cannabis (marijuana derivative) products, is pleased
to announce that we have now received verbal confirmation that
the sites of the former cancerous lesions are free of cancer cells
and we are now awaiting official Physician documentation of the
patient's history and biopsy reports.

Dr. Robert J. Melamede, the CEO and President of Cannabis
Science Inc., stated, “The photographic documentation in our
last press release, demonstrated that cannabis
extracts appeared to be effective against what seems to be the
patient's third incidence of basal cell carcinoma. For accuracy, it
should be noted that a before treatment biopsy of the lesion on the
nose was not been performed. It is obvious that there was a
lesion-centered response to the application of the cannabis
extract. This patient had a previous surgically removed lesion, as
well as a biopsied basal cell carcinoma on the right cheek. The
lesion on the cheek was also self-treated and resolved with
cannabis extracts over a half year ago. This deeper cheek lesion
did not visually respond like the lesion on the nose, hence
there is no photographic record.”

Cannabis Science is committed to making cannabis-based medicines
available to the public as rapidly as possible. The Company is
taking multiple approaches to accomplishing this aim in the
United States. The science of cannabinoids has exploded over
the past decade, laying the scientific foundation for the many
medicinal uses of this unique plant. Cannabinoids are a class
of biologically active compounds produced by all vertebrates,
the Cannabis plant, and more recently patentable synthetic
compounds produced by chemists. In fact, modern peer-reviewed
science supports the many historical uses that were discovered
over thousands of years of medicinal use by herbalists.

Dr. Melamede concludes with, “More importantly, before and
after treatment biopsies were performed and again we are very happy
to report that the sites of the former lesions have both been
verbally confirmed by a physician to be free of cancer cells and we
await the formal written documentation. The lag of the United
States federal government, and most governments world wide, to
embrace modern cannabis science has forced people to turn to
their states in an effort to make this unique medicine legally
available to suffering patients. Because of the extremely low
toxicity of cannabinoids, and generally high safety profile of
these compounds, medical marijuana patients have
become patient scientists. Rick Simpson is the leading patient
scientist to have explored the use of cannabis extracts to
treat cancers. It was because of his pioneering work, and anecdotal
reports from patient scientists from all over the world, that
Cannabis Science has been working with and educating
patients.”

Please visit
www.cannabisscience.com to view the “Breaking News”
of the successful results and images of the self-administered
cancer treatments. Cannabis Science will hold a press conference
once the official documented Physician reports are received to
formally announce its cancer formulation progress and future plans
for cancer treatments. Brand names for new cancer treatment
drugs are currently being vetted through the company attorney for
future commercial use.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The Company works
with world authorities on phytocannabinoid science targeting
critical illnesses, and adheres to scientific methodologies to
develop, produce and commercialize phytocannabinoid-based
pharmaceutical products. In sum, we are dedicated to the creation
of cannabis-based medicines, both with and without psychoactive
properties, to treat disease and the symptoms of disease, as well
as for general health maintenance.

Forward Looking Statements; This Press Release includes
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Act of
1934. A statement containing works such as "anticipate," "seek,"
intend," "believe," "plan," "estimate," "expect," "project,"
"plan," or similar phrases may be deemed "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Some or all of the events or results
anticipated by these forward-looking statements may not occur.
Factors that could cause or contribute to such differences include
the future U.S. and global economies, the impact of competition,
and the Company's reliance on existing regulations regarding the
use and development of cannabis-based drugs. Cannabis Science, Inc.
does not undertake any duty nor does it intend to update the
results of these forward-looking statements.